Bristol Myers Just Crushed Earnings, and the Real Catalyst Hasn't Even Hit Yet24/7 Wall Street • 02/05/26
Bristol Myers (BMY) Reports Q4 Earnings: What Key Metrics Have to SayZacks Investment Research • 02/05/26
Bristol Myers Squibb (BMY) Tops Q4 Earnings and Revenue EstimatesZacks Investment Research • 02/05/26
Bristol Myers Rises Inside A Buy Zone On Street-Beating 2026 OutlookInvestors Business Daily • 02/05/26
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025Business Wire • 02/05/26
OXB Signs New Multi-Year Commercial Supply Agreement with Bristol Myers SquibbGlobeNewsWire • 02/04/26
Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with BreyanziBusiness Wire • 02/04/26
Unveiling Bristol Myers (BMY) Q4 Outlook: Wall Street Estimates for Key MetricsZacks Investment Research • 02/02/26
3 Top Dividend Stocks Yielding More Than 4% to Buy Hand Over Fist This YearThe Motley Fool • 01/30/26
Bristol Myers Squibb: The Rerating Was Fast - The Proof Will Be Slow (Rating Downgrade)Seeking Alpha • 01/24/26
AI Bubble or Sustainable Growth? Here Are 2 Healthcare Companies Harnessing AI for the Long Term.The Motley Fool • 01/23/26
Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos ExpansionSeeking Alpha • 01/23/26
Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drugReuters • 01/22/26